Characteristics of Patients with Pulmonary Arterial Hypertension Receiving Selexipag in the SPHERE Registry by Race and Ethnicity
Selexipag was prescribed as part of combination therapy for PAH regardless of differing demographics and clinical characteristics across racial/ethnic groups, with no differences in selexipag discontinuation, hospitalization, and survival.
Authors
- Paul Strachan
- Nick H. Kim (ORCID: https://orcid.org/0000-0003-4702-650X)
- Kristin B. Highland (ORCID: https://orcid.org/0000-0001-5072-0725)
- Michelle Cho
- Lana Melendres‐Groves (ORCID: https://orcid.org/0009-0001-7964-8322)
- Tobore Onojighofia Tobore (ORCID: https://orcid.org/0000-0001-7334-2915)
- Murali M. Chakinala (ORCID: https://orcid.org/0000-0002-3782-341X)
- Harrison W. Farber (ORCID: https://orcid.org/0000-0002-0297-7902)
- Anna R. Hemnes (ORCID: https://orcid.org/0000-0002-2755-5845)
- Vallerie V. McLaughlin (ORCID: https://orcid.org/0000-0002-8907-1651)
- Kelly Chin (ORCID: https://orcid.org/0000-0002-1214-6723)
- Gurinderpal Doad (ORCID: https://orcid.org/0000-0002-3245-6235)
- Elham Fatehi
- Mohammad A. Rahman (ORCID: https://orcid.org/0000-0002-9971-4120)
- Michelle Han (ORCID: https://orcid.org/0000-0001-9753-7768)
Institutions
- Tufts University (US)
- Tufts Medical Center (US)
- Cleveland Clinic (US)
- Johnson & Johnson (United States) (US)
- University of New Mexico (US)
- Washington University in St. Louis (US)
- University of Michigan (US)
- University of California San Diego (US)
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Journal of Racial and Ethnic Health Disparities
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1007/s40615-025-02579-3
- Citations
- 2
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Johnson and Johnson